10 Biggest Price Target Changes For Wednesday
UBS cut the price target for Adobe Inc. (NASDAQ: ADBE) from $635 to $575. Adobe shares fell 2.3% to $541.06 in pre-market trading.
SVB Leerink Maintains Outperform on Equillium, Lowers Price Target to $14
SVB Leerink analyst Thomas Smith maintains Equillium (NASDAQ:EQ) with a Outperform and lowers the price target from $18 to $14.
45 Biggest Movers From Yesterday
Gainers
ATA Creativity Global (NASDAQ: AACG) gained 114.3% to close at $2.55.
Equillium To Reassess Potential For Its Asthma Trials
Equillium Inc's (NASDAQ: EQ) Phase 1b EQUIP study of itolizumab in patients with
Equillium Highlights Publication Of Data In ‘Journal Of Clinical Investigation’ Showing Importance Of CD6-ALCAM Pathway In Pathogenesis Of Lupus Nephritis
First data to demonstrate the contribution of CD6-ALCAM and T-cells to the pathogenesis of lupus nephritis
Largest, most comprehensive cohort of lupus nephritis patients analyzed to date supports soluble ALCAM as a
Equillium Q3 EPS $(0.35) Down From $(0.31) YoY
Equillium (NASDAQ:EQ) reported quarterly losses of $(0.35) per share. This is a 12.9 percent decrease over losses of $(0.31) per share from the same period last year.
Equillium Highlights Presentation Of Interim Safety Data From First Cohort Of Asthma Patients In Phase 1b EQUIP Study At American College Of Allergy, Asthma, Immunology Meeting Friday At 6:45 p.m. EDT
Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today reported interim data from the first
Equillium Announces Interim Safety Data And Reduction In Proteinuria For Lupus Patients Treated With Itolizumab In The EQUALISE Study Presented At The ACR Annual Meeting
Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that positive interim data
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.
